Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2026 (the company's fiscal Q4 2026 and fiscal year 2026). All dollar amounts in this news release are in US dollars unless specified otherwise. Company overview Medexus is currently focused on deliv
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-25 6:00 PM EDT | Medexus Pharmaceuticals Inc.
Envoy Medical Terminates At-the-Market (ATM) Equity Facility
White Bear Lake, Minnesota--(Newsfile Corp. - June 25, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has formally terminated its at-the-market equity facility (the "ATM Facility"). The ATM Facility, under which the Company was previously authorized to offer and sell up to $15 million worth of shares of its com
Biotechnologies, Soins de santé et hôpitaux
2026-06-25 8:30 AM EDT | Envoy Medical, Inc.
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Harvey Briggs, Chief Communications Officer, Force Family Office. Joining the
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-25 7:00 AM EDT | Phio Pharmaceuticals Corp.
Illumisoft Appoints Former White House Chief Healthcare Economist Jonathan Ketcham as Strategic Advisor
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2026) - Illumisoft Lighting Corp. (TSXV: UVC) ("Illumisoft" or the "Company") today announced the appointment of Jonathan Ketcham as a strategic advisor to the Company. Dr. Ketcham brings deep expertise in healthcare economics, public policy, reimbursement, procurement, and technology adoption. His guidance is expected to benefit Illumisoft greatly as it advances its ultraviolet germicidal technology platform toward commercializati
Technologies, Biotechnologies, Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques
2026-06-25 7:00 AM EDT | Illumisoft Lighting Corporation
Dr. Christina Rahm and DRC Ventures Accept Prestigious Gold Stevie(R) Award for Patent-Driven Manufacturing Innovation
New York, New York--(Newsfile Corp. - June 24, 2026) - Dr. Christina Rahm, founder and CEO of DRC Ventures, was honored with a Gold Stevie® Award at the 2026 American Business Awards® ceremony in New York City for her groundbreaking work in developing the patent-driven manufacturing infrastructure
Biotechnologies, Aliments / boissons, Santé
2026-06-24 1:20 PM EDT | DRC Ventures
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - June 24, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-24 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test
Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies focused on the early detection of lung cancer through metabolomics, today announced a major operational milestone that underscores the strength of Canadian life sciences innovation. Coinciding with the global spotlight on Canadian medical innovation taking the stage at the BIO Int
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-06-23 8:30 AM EDT | BioMark Diagnostics, Inc.
Therma Bright Announces Expanded U.S. Orders for Venowave and Mobilizes Supply Chain for Upcoming Sales Volume
Toronto, Ontario--(Newsfile Corp. - June 23, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, is pleased to announce continued sales momentum for its Venowave mobile compression device in the United States, highlighted by additional follow-on orders from Horizon Health USA ("Horizon") and from Gen-X Med. Building on the rapid deployment of previous ship
Technologies, Biotechnologies, Santé
2026-06-23 6:30 AM EDT | Therma Bright Inc.
Yellowbird Diagnostics Completes Dosing in First-in-Human Phase 1 Trial of NeuCaVis(TM)
Ottawa, Ontario--(Newsfile Corp. - June 22, 2026) - Yellowbird Diagnostics Inc. today announced the successful completion of dosing and imaging in its first-in-human Phase 1 clinical trial of NeuCaVis™, a novel F18 PET radiotracer designed to image inflammation. Led by Dr. Benjamin Chow, the study enrolled twelve healthy volunteers,
Biotechnologies, Pharmaceutique
2026-06-22 7:51 AM EDT | Yellowbird Diagnostics
Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement
Houston, Texas--(Newsfile Corp. - June 22, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the beginning of a new commercial chapter for VitaCookies with the signing of its first licensing agreement. This milestone moves VitaCookies from internal development toward commercial execution, positioning the brand as a structured growth opportunity built on CBIH's formulations, operatio
Biotechnologies, Pharmaceutique, Cannabis, Santé
2026-06-22 7:00 AM EDT | Cannabis Bioscience International Holdings
MustGrow Closes $3.7 Million Non-Brokered LIFE Offering
Saskatoon, Saskatchewan--(Newsfile Corp. - June 19, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the closing of its previously announced non-brokered private placement of 7,481,541 units of the Company (each, a "Unit") at a price of $0.50 per Unit for gross proceeds of approximately $3,741,000 (the "LIFE Offering"). Each Unit consists of (i) one common share of the Company (each
Agriculture, Biotechnologies, Cannabis, Sélectionneurs de cannabis
2026-06-19 5:00 PM EDT | MustGrow Biologics Corp.
Neural Therapeutics Inc. Announces Transition to Semi-Annual Financial Reporting
Toronto, Ontario--(Newsfile Corp. - June 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions provided under Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933"). Introduced by the Canadian Securities Administrators ("CSA"), the pilot program under
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-06-19 12:16 PM EDT | Neural Therapeutics Inc.
Envoy Medical to Present at Investor Conferences on June 25th
White Bear Lake, Minnesota--(Newsfile Corp. - June 18, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Virtual Life Sciences Investor Forum and the Biotech Webull Webinar Panel on June 25, 2026. Life Sciences Virtual Investor Forum
Biotechnologies, Soins de santé et hôpitaux
2026-06-18 8:30 AM EDT | Envoy Medical, Inc.
BioHarvest Sciences to Present at the 2026 BIO International Convention
British Columbia and Rehovot, Israel--(Newsfile Corp. - June 18, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will present at the upcoming BIO International Convention, to be held on June 22-25, in San Diego, California. Presentation Details:
Biotechnologies, Pharmaceutique, Santé
2026-06-18 7:30 AM EDT | BioHarvest Sciences Inc.
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-18 7:00 AM EDT | Phio Pharmaceuticals Corp.
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
Encinitas, California--(Newsfile Corp. - June 18, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data showing that KIO-300, part of the company's novel ion channel modulator platform, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA. "These data reinforce
Biotechnologies, Pharmaceutique
2026-06-18 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Restart Life Advances AI-Driven E-Commerce Strategy to Scale Online Sales Growth for Holy Crap Foods
Vancouver, British Columbia--(Newsfile Corp. - June 18, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc., is preparing to begin harnessing predictive AI to further its e-commerce consumer and wholesale sales platform. The initiative is engineered to leverage readily available predictive consumer behavior models to optimize, monetize, and scale the brand'
Technologies, Biotechnologies, Santé
2026-06-18 6:00 AM EDT | Restart Life Sciences Corp.
MustGrow Increases Non-Brokered LIFE Offering to Approximately $3.7 Million
Saskatoon, Saskatchewan--(Newsfile Corp. - June 17, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTC: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce that, in connection with its previously announced non-brokered private placement of units (each, a "Unit") at a price of $0.50 per Unit, and as a res
Agriculture, Biotechnologies, Cannabis, Sélectionneurs de cannabis
2026-06-17 7:21 PM EDT | MustGrow Biologics Corp.
Hemostemix' $1,000,000 Private Placement and Update
Calgary, Alberta--(Newsfile Corp. - June 17, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that the Company is closing up to $1,000,000 of financing in tranches from the sale of Units at $0.05 each. Each Unit shall consist of one Common Share in the capital of the Company ("Common Share") and one half common share purchase warrant ("1/2 Warrant"), with each whole Warrant (2 x 1/2 Warrants) entitling the holder to acquire one Common Share at a price of $
Biotechnologies, Pharmaceutique, Santé
2026-06-17 5:22 PM EDT | Hemostemix Inc.
Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions
Montreal, Quebec--(Newsfile Corp. - June 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce its participation in the BIO International Convention 2026, taking place June 22-25 in San Diego, California. Defence's team will be available throughout the conference to meet with pharmaceutical and biotechnology companies, investors, an
Biotechnologies, Pharmaceutique, Santé
2026-06-17 3:15 AM EDT | Defence Therapeutics Inc.